CRISPR booked revenue of just under $36 million. On the bottom line, CRISPR flipped to a generally accepted accounting ...
Researchers have been "making great inroads" in precision medicine, and a 15 percent cap on indirect costs could quash the momentum, experts worry.
CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is ...
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback